Supernus Pharmaceuticals, Inc.

NASDAQ:SUPN

Drug Manufacturers - Specialty & Generic

Healthcare
$28.96 +1.17%

+$0.51 today

Market cap
$6.02B
Beta
0.54
P/E (TTM)
-87.6
EPS (TTM)
-$0.50
52W Low $30.83High $59.68

Volume 2.71M

Average 0.64M

SUPN EBITDA Margin

EBITDA as a percentage of revenue.

Supernus Pharmaceuticals, Inc.NASDAQ: SUPN

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin narrows to -13.5%

EBITDA Margin was -13.5% in Q2 FY2026, down 36.5 pp from a year earlier. On a trailing-twelve-month basis it was -1.9%, down 26.9 pp year over year. Over 3 fiscal years it narrowed by 17.1 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 1 analysts of 38.5% for the fiscal year ending Dec 2026, up from 5.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-13.5%-23.2 pp QoQ
Last fiscal yearDec 2025
5.9%-21.0 pp YoY
LTMJun 2026
-1.9%-26.9 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-36.5 pp+76.3 pp+112.7 pp
1 year-21.0 pp+32.6 pp+53.6 pp
3 years-17.1 pp+30.0 pp+47.0 pp
5 years+35.3 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
5.9%
Year-over-year change
-21.0pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How SUPN compares with its peers on the latest reported figures

  • SUPN's LTM Jun 2026 EBITDA Margin of -1.9% is the lowest of the 3 companies compared; the peer median is 43.4%.
  • Its year-over-year change of -26.9 pp is the lowest of 3, against a peer median of +4.0 pp.
  • Over three fiscal years its change of -17.1 pp compares with a peer median of +15.5 pp.
SUPN Competitors Peer median
EBITDA Margin for SUPN and competitors
Company Period LTM level YoY 3-year change
COLLCollegium Pharmaceutical, Inc.LTM Mar 202676.6% +26.5 pp+14.0 pp
ALKSAlkermes plcLTM Sep 202610.2% -18.5 pp+17.0 pp
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026-1.9% -26.9 pp-17.1 pp
Peer median (excluding SUPN) 43.4%+4.0 pp+15.5 pp

Competitors are the stored peer set for SUPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue579.78M667.24M607.52M661.82M718.95M
Cost of Revenue75.06M87.22M83.78M77.91M74.56M
Gross Profit504.71M580.02M523.74M583.91M644.39M
Gross Margin87.1%86.9%86.2%88.2%89.6%
Research & Development90.47M74.55M91.59M108.8M106.24M
Selling, General & Admin304.76M377.22M336.36M335.78M485.56M
Operating Expenses418.69M533.89M529.01M502.25M681.25M
Depreciation & Amortization32.6M85.54M84.86M80.41M91.56M
EBITDA129.19M153.36M90.04M178.28M42.53M
EBITDA Margin22.3%23.0%14.8%26.9%5.9%
Operating Income86.03M46.12M(5.27M)81.67M(36.86M)
Operating Margin14.8%6.9%-0.9%12.3%-5.1%
Interest Income10.57M21.69M10.45M16.2M13.25M
Interest Expense23.42M7.07M2.42M00
Other Income / Expenses(12.85M)14.62M8.04M16.2M(12.17M)
Income Before Tax73.18M60.74M2.77M97.87M(49.03M)
Pre-Tax Margin12.6%9.1%0.5%14.8%-6.8%
Income Tax Expense19.75M32K1.45M24.01M(10.48M)
Net Income53.42M60.71M1.32M73.87M(38.55M)
Net Margin9.2%9.1%0.2%11.2%-5.4%
EPS (Basic)1.011.130.021.34(0.68)
EPS (Diluted)0.981.040.021.32(0.68)
Weighted Avg Shares53.1M53.67M54.54M55.1M56.45M
Weighted Avg Shares (Diluted)54.36M61.68M55.51M55.96M56.45M

Supernus Pharmaceuticals, Inc.

NASDAQ:SUPN

Intrinsic Alpha fair value

Locked

Current Price

$28.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.